Edelson Lechtzin LLP is investigating securities fraud claims on behalf of investors in Akero Therapeutics, Inc. (NASDAQ: AKRO)…
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…
Radnor, Pa., May 11, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP…
SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who…
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a…
NEW ORLEANS, May 07, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former…
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
RADNOR, Pa., May 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP…
SAN DIEGO, May 04, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that it has…
NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP announces that a…
SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who…
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally…
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW ORLEANS, April 30, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former…
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action…
The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm…
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that it has…
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
…
Akero Therapeutics executive sells over $20k in company stock…
Akero Therapeutics CEO sells over $55k in company stock…
Akero Therapeutics COO sells shares worth over $18,000…
Akero Therapeutics CFO sells shares to cover tax withholding…
Akero Therapeutics CSO sells shares worth over $17k…
SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational…
Akero Therapeutics prices public stock offering at $29 per share…
…
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company…
LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company…
Akero Therapeutics launches $300 million stock offering…
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company…
Akero Therapeutics reports positive EFX trial results…
The mean of analysts price targets for Akero Therapeutics, Inc. (AKRO) points to a 58.9% upside in the stock. While…